Isolation and Characterization of A Panel of Anti-HER2 Scfv Molecules by Phage Display Technology

Document Type : Original Article


1 Ph.D. Student of Genetics, College of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran. Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran. Visiting Researcher at Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.

2 Professor, Department of Genetics, College of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran. Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.

3 Associate Professor, Department of Genetics,College of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran. Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.

4 Associate Professor, Department of Molecular Cell Biology, College of Applied Sciences, Ferdowsi University of Mashhad, Mashhad, Iran. Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.

5 Associate Professor, Department of Physiology, College of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran. Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.

6 Associate Professor, Department of Medical Oncology,Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.

7 Professor, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.


Introduction: The scFvs (single-chain fragment variable) are popular recombinant antibody formats that are produced by advanced molecular biology and genetic engineering techniques. Moreover, HER2-ECD recognized as a suitable target for a wide range of cancer cells. The current study was accomplished for isolation of specific scFv antibodies.
Methods: To isolate specific scFv fragments from phage library, phage display technology was carried out by coating HER2 extra cellular domain (HER2-ECD) protein onto an immuno tube. The resultant scFv antibodies were expressed in Escherichia coli TG1. The recombinant products were purified by metal affinity chromatography against His-tag. These scFvs were characterized for binding to HER2-ECD by western blot, biosensor surface resonance and flow cytometry assays.
Results: After three rounds of panning against HER2-ECD protein yielded three different scFv fragments that confirmed by subsequent DNA sequencing. The kinetic results indicated that all of isolated scFvs had binding tendency to HER2-ECD on micro molar to nano molar range. Western blot and flow cytometry results demonstrated that all of isolated scFvs have had binding tendency to HER2-ECD.
Conclusion: Phage display is a powerful tool for isolate promising scFv clones that bind specifically to the HER2 receptor, a cell surface of breast cancer antigen.


  1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005 Sep;23(9):1147-.75
  2. Souriau C, Hudson PJ. Recombinant antibodies for cancer diagnosis and therapy. Expert Opin on Biolog Ther 2003 Apr;3(2):305-18.
  3. Arteaga CL. ERBB receptors in cancer: signaling from the inside. Breast Cancer Res 2011 Mar;13(2):304.
  4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001 Feb;2(2):127-37.
  5. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008 Sep;19(9):1523-9.
  6. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000 Jul;19(13):3159-67.
  7. Sevcikova K, Vertakova-Krakovska B, Spanik S. Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer. ISRN Oncol 2013 May 23;2013:362467.
  8. Chang HW, Nguyen DD, Washington E, Walker ID, Holloway SA. Phage display antibodies to allelic determinants of canine blood cells. J Immunol Methods 2006 Apr 20;311(1-2):1-11.
  9. Marcus WD, Wang H, Lohr D, Sierks MR, Lindsay SM. Isolation of an scFv targeting BRG1 using phage display with characterization by AFM. Biochem Bioph Res Commun 2006 Apr 21;342(4):1123-9.
  10. Rodriguez-Diaz J, Monedero V, Perez-Martinez G, Buesa J. Single-chain variable fragment (scFv) antibodies against rotavirus NSP4 enterotoxin generated by phage display. J Virol Methods 2004 Nov;121(2):231-8.
  11. Carter P, Smith L, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 2004 Dec;11(4):659-87.
  12. Davis CG, Jia XC, Feng X, Haak-Frendscho M. Production of human antibodies from transgenic mice. Methods Mol Biol 2004;248:191-200.
  13. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Ann R Immunol 1994;12:433-55.
  14. Brockmann EC, Vehniainen M, Pettersson K. Use of high-capacity surface with oriented recombinant antibody fragments in a 5-min immunoassay for thyroid-stimulating hormone. Anal Biochem 2010 Jan 15;396(2):242-9.
  15. Hock B, Seifert M, Kramer K. Engineering receptors and antibodies for biosensors. Biosens Bioelectron 2002 Mar;17(3):239-49.
  16. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000 Feb 11;296(1):57-86.
  17. Maynard J, Georgiou G. Antibody engineering. Ann Rev Biomed Eng 2000;2:339-76.
  18. Coomber DW. Panning of antibody phage-display libraries. Standard protocols. Methods Mol Biol 2002;178:133-45.
  19. Romanov VI. Phage display selection and evaluation of cancer drug targets. Curr Cancer Drug Targets 2003 Apr;3(2):119-29.
  20. Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Biopolymers 2002;66(3):184-99.
  21. Schirrmann T, Meyer T, Schutte M, Frenzel A, Hust M. Phage display for the generation of antibodies for proteome research, diagnostics and therapy. Molecules 2011 Jan 10;16(1):412-26.
  22. Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, et al. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J 1994 Feb 1;13(3):692-8.
  23. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991 Dec 5;222(3):581-97.
  24. Sambrook J, Russell DW. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor, NY:Cold Spring Harbor Laboratory Press;2001:1-2344.
  25. Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, Bosshard HR, et al. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods 1997 Feb 14;201(1):35-55.
  26. Yuan QA, Simmons HH, Robinson MK, Russeva M, Marasco WA, Adams GP. Development of engineered antibodies specific for the Mullerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol Cancer Ther 2006 Aug;5(8):2096-105.
  27. Martin AC. Accessing the Kabat antibody sequence database by computer. Proteins 1996 May;25(1):130-3.
  28. Kabat EA, Wu TT. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementaritydetermining regions to binding of antibody-combining sites. J Immunol 1991 Sep 1;147(5):1709-19.
  29. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976 May 7;72:248-54.
  30. Singh A, Poshtiban S, Evoy S. Recent advances in bacteriophage based biosensors for food-borne pathogen detection. Sensors (Basel) 2013 Jan 30;13(2):1763-86.             
  31. Abdiche YN, Lindquist KC, Stone DM, Rajpal A, Pons J. Label-free epitope binning assays of monoclonal antibodies enable the identification of antigen heterogeneity. J Immunol Methods 2012 Aug 31;382(12):101-16.
  32. Bee C, Abdiche YN, Stone DM, Collier S, Lindquist KC, Pinkerton AC, et al. Exploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactions. Plos One 2012;7(4):e36261.
  33. Abdiche Y, Malashock D, Pinkerton A, Pons J. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal Biochem 2008 Jun 15;377(2):209-17.
  34. Bee C, Abdiche YN, Pons J, Rajpal A. Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum. Plos One 2013 Nov 6;8(11):e80501.
  35. Geuijen CA, Clijsters-van der Horst M, Cox F, Rood PM, Throsby M, Jongeneelen MA, et al. Affinity ranking of antibodies using flow cytometry: application in antibody phage display-based target discovery. J Immunol Methods 2005 Jul;302(1-2):68-77.
  36. Ladner RC, Sato AK, Gorzelany J, de Souza M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 2004 Jun 15;9(12):525-9.
  37. Thie H, Meyer T, Schirrmann T, Hust M, Dubel S. Phage display derived therapeutic antibodies. Curr Pharm Biotechnol 2008 Dec;9(6):439-46.
  38. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009 Apr;27(4):331-7.
  39. Hirose M, Hayano T, Shirai H, Nakamura H, Kikuchi M. Isolation of anti-glutathione antibodies from a phage display library. Protein Eng 1998 Mar;11(3):243-8.
  40. Khan NA, Greenman J, Topping KP, Hough VC, Temple GS, Paget TA. Isolation of Acanthamoebaspecific antibodies from a bacteriophage display library. J Clin Microbiol 2000 Jun;38(6):2374-7.
  41. Vitaliti A, Wittmer M, Steiner R, Wyder L, Neri D, Klemenz R. Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. Cancer Res 2000 Aug 15;60(16):4311-4.
  42. Ayat H, Burrone OR, Sadghizadeh M, Jahanzad E, Rastgou N, Moghadasi S, et al. Isolation of scFv antibody fragments against HER2 and CEA tumor antigens from combinatorial antibody libraries derived from cancer patients. Biologicals 2013 Nov;41(6):345-.45
  43. Adams GP, Schier R. Developing Anti-HER2/neu Single-Chain Fv Fragments from Phage Display Libraries. Methods Mol Med 2001;39:729-.74
  44. Drebin JA, Link VC, Weinberg RA, Greene MI. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci U SA 1986 Dec;83(23):9129-33.
  45. Schirrmann T, Al-Halabi L, Dubel S, Hust M. Production systems for recombinant antibodies. Front Biosci 2008 May 1;13:4576-.49
  46. de Graaf M, van der Meulen-Muileman IH, Pinedo HM, Haisma HJ. Expression of scFvs and scFv fusion proteins in eukaryotic cells. Methods Mol Biol 2002;178:379-87.
  47. O'Brien PM, Aitken R. Broadening the impact of antibody phage display technology. Amplification of immunoglobulin sequences from species other than humans or mice. Methods Mol Biol 2002;178:73-86. Review.
  48. Mergulhao FJ, Monteiro GA. Periplasmic targeting of recombinant proteins in Escherichia coli. Methods Mol Biol 2007;390:47-.16
  49. Kipriyanov SM. High-level periplasmic expression and purification of scFvs. Methods Mol Biol 2002;178:333-41.
  50. Ceran C, Cokol M, Cingoz S, Tasan I, Ozturk M, Yagci T. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-alpha. BMC Cancer 2012 Oct 4;12:450.